0.25 Semaglutide: What the Starting Dose Does

0.25 semaglutide is the entry dose of the GLP-1 medication semaglutide, injected once a week for the first four weeks of treatment. It is a titration step designed to let the body adjust to the drug rather than a dose that delivers full weight loss or blood sugar control on its own. Both Ozempic and Wegovy start patients at 0.25 mg before moving up.

What 0.25 mg Semaglutide Is and What It Does

Semaglutide is a GLP-1 receptor agonist. It mimics a hormone your gut releases after meals, which slows how quickly food leaves the stomach and increases feelings of fullness.

The 0.25 mg dose is small on purpose. It is roughly one-tenth of Wegovy's maximum maintenance dose of 2.4 mg per week.

• It is a starter dose, not a target dose. Prescribers generally do not expect major weight loss at 0.25 mg.
• It is given once weekly on the same day each week, by subcutaneous injection into the abdomen, thigh, or upper arm.
• It may mildly reduce appetite, but most people notice the biggest changes after the dose increases.

Semaglutide is FDA-approved under the brand names Ozempic, Wegovy, and Rybelsus. Compounded semaglutide sold online is not FDA-approved and has not been reviewed for safety, effectiveness, or purity.

Where 0.25 mg Fits in the Dose Schedule

Dose increases usually happen no faster than every four weeks. That pace gives the body time to adapt and keeps side effects manageable.

Product	Starting dose	Step 2	Step 3	Step 4	Maximum
Wegovy (weight management)	0.25 mg	0.5 mg	1 mg	1.7 mg	2.4 mg
Ozempic (type 2 diabetes)	0.25 mg	0.5 mg	1 mg	2 mg	2 mg

Ozempic and Wegovy share the same starting dose but different targets. Ozempic is approved for type 2 diabetes and tops out at 2 mg weekly, while Wegovy is approved for weight management and escalates to 2.4 mg weekly.

How Many Units Is 0.25 mg of Semaglutide?

People who use vials and insulin syringes often ask how many units is 0.25 mg of semaglutide. There is no single answer, because the number of units depends entirely on the concentration of the liquid in the vial.

Concentration	Volume for 0.25 mg	Units on a U-100 syringe
0.5 mg/mL	0.5 mL	50 units
1 mg/mL	0.25 mL	25 units
2.5 mg/mL	0.1 mL	10 units
5 mg/mL	0.05 mL	5 units

U-100 syringes are calibrated so that 100 units equal 1 mL. Drawing a 5-unit dose accurately is difficult, which makes high-concentration vials a common source of dosing mistakes.

FDA-approved semaglutide pens are pre-filled and pre-dosed. No unit conversion is needed when Ozempic or Wegovy is used as labeled, because the pen delivers 0.25 mg based on the manufacturer's set dose counter.

What to Expect During the First Four Weeks

• Nausea is the most common side effect and often fades once the dose is stable.
• Constipation, burping, and feeling full quickly are also frequently reported.
• Weight loss at 0.25 mg is usually modest — often a few pounds at most.
• Blood sugar improvements at this dose tend to be small.

Serious but uncommon risks include pancreatitis, gallbladder disease, and bowel obstruction. The FDA boxed warning notes thyroid C-cell tumors observed in rodents, and semaglutide is not recommended for people with a personal or family history of medullary thyroid carcinoma or MEN2.

Compounded Products, Peptides, and Reconstitution

Compounded semaglutide is sometimes supplied as a lyophilized powder that must be mixed with bacteriostatic water before injection. A bacteriostatic water 25 pack is a common supply item for people handling these vials. Bacteriostatic water contains benzyl alcohol and is labeled for use with multi-dose vials, not for intravenous injection.

Non-FDA-approved peptides are frequently discussed alongside semaglutide. A cagrilintide and semaglutide blend appears in research literature as CagriSema, an investigational combination that is not approved in any form. A stack described as aod 9604 and semaglutide has likewise not been evaluated in FDA-approved clinical trials.

Research-use-only peptides are not manufactured for human consumption. Sterility, purity, and actual peptide content are not guaranteed.

How 0.25 mg Compares With Other Options

Comparing retatrutide vs tirzepatide vs semaglutide at the starting dose is not a fair comparison. Each drug uses a different titration schedule and a different maximum dose.

Tirzepatide (Mounjaro, Zepbound) starts at 2.5 mg weekly. Retatrutide is not FDA-approved and remains under clinical investigation, so it has no established starting dose for patients.

What matters more than the first number is how well you tolerate the titration and whether your prescriber adjusts the plan based on your side effects and results.

Safety and Next Steps

0.25 mg semaglutide is not a maintenance dose for most people, and staying on it longer than four weeks is a clinical decision rather than a self-directed one.

Talk to a licensed healthcare professional before starting, stopping, or changing any semaglutide dose. Do not increase faster than your prescriber recommends, even if your appetite returns.

COMMON QUESTIONS

Frequently Asked Questions

Is 0.25 mg of semaglutide enough to lose weight?

For most people, 0.25 mg is not enough to produce meaningful weight loss. It is a titration dose that lets the body adjust before higher doses are introduced. Some people notice reduced appetite and a few pounds of loss in the first four weeks, but the larger effects in clinical trials appeared at 1.7 mg and 2.4 mg of Wegovy.

How many units is 0.25 mg of semaglutide?

The number of units depends on the concentration of the solution. At 1 mg/mL, 0.25 mg equals 25 units on a U-100 syringe; at 2.5 mg/mL it equals 10 units; at 5 mg/mL it equals 5 units. FDA-approved Ozempic and Wegovy pens are pre-dosed, so no unit conversion is needed.

How long should I stay on 0.25 mg of semaglutide?

The labeled schedule keeps most patients at 0.25 mg for four weeks before increasing to 0.5 mg. If side effects are troublesome, a prescriber may extend that period. Never extend or shorten this step without medical guidance.